✦ LIBER ✦

Complete remission of renal cell carcinoma with lung metastases in two hemodialysis patients after low-dose interferon therapy

✍ Scribed by Kaoru NEMOTO; Takafumi MIURA; Go SHIOJI; Narumi TSUBOI

Book ID: 109227793
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 812 KB
Volume: 15
Category: Article
ISSN: 1492-7535
DOI: 10.1111/j.1542-4758.2011.00540.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Complete remission of bulky lung metasta

Complete remission of bulky lung metastases of renal cell carcinoma by low-dose interferon-alpha monotherapy

✍ Seiichi Orikasa; Kouichi Kanbe; Izuru Minemura 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 302 KB

A case of renal cell carcinoma with mult

A case of renal cell carcinoma with multiple lung metastases refractory to interferon-α showing complete remission by interleukin-2 monotherapy

✍ TETSUYA HAYASHI; YASUSHI MIYAGAWA; AKIRA TSUJIMURA; NORIO NONOMURA; MASATO MINAM 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB

Long-term complete response to very-low-

Long-term complete response to very-low-dose interleukin-2 therapy in patients with metastatic renal cell carcinoma: report of two cases

✍ Ken-ichi Harada; Hideaki Miyake; Toshifumi Kurahashi; Masato Fujisawa 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 333 KB

Long-term immunotherapy with low-dose in

Long-term immunotherapy with low-dose interleukin-2 and interferon-α in the treatment of patients with advanced renal cell carcinoma

✍ Carlo Buzio; Simeone Andrulli; Rosaria Santi; Laura Pavone; Rodolfo Passalacqua; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 1 views

Cytotoxic In vitro function in patients

Cytotoxic In vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy effects of activation with recombinant interleukin-2

✍ Cristina Feruglio; Renato Zambello; Livio Trentin; Pietro Bulian; Tiziano France 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 658 KB

Upfront, randomized, phase 2 trial of so

Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma : Clinical and biomarker analysis

✍ Eric Jonasch; Paul Corn; Lance C. Pagliaro; Carla L. Warneke; Marcella M. Johnso 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

## Abstract ## BACKGROUND: The objective of this study was to independently evaluate the objective response rate of sorafenib and sorafenib plus low‐dose interferon‐alfa 2b (IFN) as frontline therapy in patients with metastatic renal cell carcinoma (mRCC). ## METHODS: Untreated patients with cle